R&D News | pharmaphorum

News

Bayer names Christoph Koenen as its new CMO

Bayer has looked internally for its chief medical officer, appointing Christoph Koenen to the post alongside his current clinical development role.

News

Sanofi forges new $8bn pact with Regeneron

Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a new deal – including a $1bn upfront payment – that spans four new drugs.

News

Woman holds a pill between index finger and thumb

New Lilly combo tops tirzepatide for weight loss in diabetes

Eli Lilly's bid to dominate the next generation of weight-loss therapies has been strengthened by data on its new combination therapy EloraTZP.

News

Apogee buy delivers eczema trial win for AbbVie

AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.

News

Lilly fleshes out triple G data in diabetes and obesity

Eli Lilly has revealed more data with its triple G agonist retatrutide, boosting its credentials as the next big thing in cardiometabolic diseases.

News

uniQure falls on long-term Huntington's gene therapy data

uniQure's latest data drop for its gene therapy for Huntington's disease, under review in the US and UK, has spooked investors.

Bayer names Christoph Koenen as its new CMO

Sanofi forges new $8bn pact with Regeneron

New Lilly combo tops tirzepatide for weight loss in diabetes

Apogee buy delivers eczema trial win for AbbVie

Lilly fleshes out triple G data in diabetes and obesity

uniQure falls on long-term Huntington's gene therapy data

AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks